Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This observational protocol will allow for an independent, prospective evaluation of the improvement in survival of patients with Fanconi disease in hematological deadlock due to the absence of an HLA-identical donor and having received a haploidentical transplant.
Fanconi's disease is characterised by a constitutional defect in DNA repair which results in the occurrence of bone marrow failure and haematological malignancies, mainly myeloid: at the age of 40, the cumulative incidence of these two types of pathology reaches almost 100%. The only curative treatment for haemtalogocial diseases is allogenic hematopoietic stem cell transplant. Transplantation modalities must be adapted to the particular susceptibility of these patients to DNA bridging agents and radiotherapy. HSC transplantation is indicated with an unaffected matched related or matched unrelated donor when the patient has severe bone marrow failure or a poor prognostic clonal evolution (cytogenetic evolution or proven haemopathy). Alternative transplants (9/10 pheno-identical, haplo-identical and placental blood donors) were no longer proposed in most cases due to the frequency of severe complications (graft-versus-host disease, viral infections) and the catastrophic medium-term survival of around 40% (Dufort, Bone Marrow Transplant 2012, Gluckman Biol Blood Marrow Transplant. 2007). The development over the last decade of new haploidentical or phenoidentical 9/10 transplant protocols with unmodified grafts and GVH prophylaxis with post-transplant cyclosphosphamide or ex vivo T-depletion adapted to the particular susceptibility of patients with Fanconi disease has reduced the incidence of these severe complications.
This observational protocol will allow for an independent, prospective evaluation of the improvement in survival of patients with Fanconi disease in hematological deadlock due to the absence of an HLA-identical donor and having received a haploidentical transplant
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Patient with Fanconi disease |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Blood sampling | Other | Additional blood samples at J100, M6, M12, M24 |
|
| Measure | Description | Time Frame |
|---|---|---|
| Overall Survival Rate | 2 years after transplant |
| Measure | Description | Time Frame |
|---|---|---|
| Engraftment | Engraftment at least 3 consecutive days with neutrophils > 0.5 G/L and 7 consecutive days with platelets > 20 G/L, with predominantly whole blood donor chimerism | At day 100 |
| Absolute neutrophils count |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Patient with Fanconi disease
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Flore Sicre de Fontbrune, Dr | Contact | +33 1 42 49 42 67 | flore.sicre-de-fontbrune@aphp.fr | |
| Matthieu RESCHE-RIGON, Pr | Contact | +33 1 42 49 97 42 | matthieu.resche-rigon@u-paris.fr |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D005198 | Fanconi Syndrome |
| ID | Term |
|---|---|
| D015499 | Renal Tubular Transport, Inborn Errors |
| D007674 | Kidney Diseases |
| D014570 | Urologic Diseases |
| D052776 | Female Urogenital Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D001800 | Blood Specimen Collection |
| ID | Term |
|---|---|
| D013048 | Specimen Handling |
| D019411 | Clinical Laboratory Techniques |
| D019937 | Diagnostic Techniques and Procedures |
| D003933 | Diagnosis |
Not provided
Not provided
Not provided
Not provided
Not provided
| At 1 month |
| Absolute neutrophils count | At 3 months |
| Absolute neutrophils count | At 6 months |
| Absolute neutrophils count | At 12 months |
| Absolute neutrophils count | At 24 months |
| Absolute number of platelets | At 1 month |
| Absolute number of platelets | At 3 months |
| Absolute number of platelets | At 6 months |
| Absolute number of platelets | At 12 months |
| Absolute number of platelets | At 24 months |
| Incidence of grade 2 to 4 Acute Graft versus Host Disease | At 3 months |
| Incidence of Acute cortico-resistant Graft versus Host Disease | At 3 months |
| Incidence of Chronic Graft versus Host Disease | At 24 months |
| Incidence of relapse | At 12 months |
| Incidence of relapse | At 24 months |
| Progression free survival | At 12 months |
| Progression free survival | At 24 months |
| Incidence of reactivation of cytomegalovirus infection | At 12 months |
| Incidence of reactivation of Epstein Barr virus infection | At 12 months |
| Incidence of severe infection of grade 4 and above according to Common Terminology Criteria for Adverse Events (CTCAE) | At 3 months |
| Incidence of severe infection of grade 4 and above according to Common Terminology Criteria for Adverse Events (CTCAE) | At 6 months |
| Incidence of severe infection of grade 4 and above according to Common Terminology Criteria for Adverse Events (CTCAE) | At 12 months |
| Incidence of severe infection of grade 4 and above according to Common Terminology Criteria for Adverse Events (CTCAE) | At 24 months |
| Graft-versus-host disease-free, relapse-free survival (GRFS) | At 24 months |
| Incidence of cardiac toxities | At 12 months |
| Overall survival | At 12 months |
| Quality of Life questionnaire for adults | Quality of life will be assessed for adult using "European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (QLQ) " EORTC QLQ-C30-V3 questionnaire.The QLQ-C30 is composed of both multi-item scales and single-item measures. All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level. | At inclusion |
| Quality of Life questionnaire for adults | Quality of life will be assessed for adult using "European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (QLQ) " EORTC QLQ-C30-V3 questionnaire.The QLQ-C30 is composed of both multi-item scales and single-item measures. All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level. | At 3 months |
| Quality of Life questionnaire for adults | Quality of life will be assessed for adult using "European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (QLQ) " EORTC QLQ-C30-V3 questionnaire.The QLQ-C30 is composed of both multi-item scales and single-item measures. All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level. | At 6 months |
| Quality of Life questionnaire for adults | Quality of life will be assessed for adult using "European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (QLQ) " EORTC QLQ-C30-V3 questionnaire.The QLQ-C30 is composed of both multi-item scales and single-item measures. All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level. | At 12 months |
| Quality of Life questionnaire for adults | Quality of life will be assessed for adult using "European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (QLQ) " EORTC QLQ-C30-V3 questionnaire.The QLQ-C30 is composed of both multi-item scales and single-item measures. All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level. | At 24 months |
| Quality of life questionnaire for minors | Quality of life will be assessed for minor using The Pediatric Quality of Life Inventory™ (PedsQL™) The 36-item PedsQL™ Family Impact Module is a parent-report instrument designed to assess the impact of pediatric chronic health conditions on parents and the family. It includes 6 subscales measuring parents' self-reported functioning. The scale has five Likert response options, 'never', 'almost never', 'sometimes', 'often' and 'almost always' (corresponding to scores of 100, 75, 50, 25 and 0). Higher scores indicate better functioning. | At inclusion |
| Quality of life questionnaire for minors | Quality of life will be assessed for minor using The Pediatric Quality of Life Inventory™ (PedsQL™) The 36-item PedsQL™ Family Impact Module is a parent-report instrument designed to assess the impact of pediatric chronic health conditions on parents and the family. It includes 6 subscales measuring parents' self-reported functioning. The scale has five Likert response options, 'never', 'almost never', 'sometimes', 'often' and 'almost always' (corresponding to scores of 100, 75, 50, 25 and 0). Higher scores indicate better functioning. | At 3 months |
| Quality of life questionnaire for minors | Quality of life will be assessed for minor using The Pediatric Quality of Life Inventory™ (PedsQL™) The 36-item PedsQL™ Family Impact Module is a parent-report instrument designed to assess the impact of pediatric chronic health conditions on parents and the family. It includes 6 subscales measuring parents' self-reported functioning. The scale has five Likert response options, 'never', 'almost never', 'sometimes', 'often' and 'almost always' (corresponding to scores of 100, 75, 50, 25 and 0). Higher scores indicate better functioning. | At 6 months |
| Quality of life questionnaire for minors | Quality of life will be assessed for minor using The Pediatric Quality of Life Inventory™ (PedsQL™) The 36-item PedsQL™ Family Impact Module is a parent-report instrument designed to assess the impact of pediatric chronic health conditions on parents and the family. It includes 6 subscales measuring parents' self-reported functioning. The scale has five Likert response options, 'never', 'almost never', 'sometimes', 'often' and 'almost always' (corresponding to scores of 100, 75, 50, 25 and 0). Higher scores indicate better functioning. | At 12 months |
| Quality of life questionnaire for minors | Quality of life will be assessed for minor using The Pediatric Quality of Life Inventory™ (PedsQL™) The 36-item PedsQL™ Family Impact Module is a parent-report instrument designed to assess the impact of pediatric chronic health conditions on parents and the family. It includes 6 subscales measuring parents' self-reported functioning. The scale has five Likert response options, 'never', 'almost never', 'sometimes', 'often' and 'almost always' (corresponding to scores of 100, 75, 50, 25 and 0). Higher scores indicate better functioning. | At 24 months |
| Rate of chimerism | At 1 month |
| Rate of chimerism | At 3 months |
| Rate of chimerism | At 6 months |
| Rate of chimerism | At 12 months |
| Rate of chimerism | At 24 months |
| Immune reconstitution by analyzing T, B, natural killer (NK), regulatory T cell levels in the peripheral blood | 3 months after transplant |
| Immune reconstitution by analyzing T, B, natural killer (NK), regulatory T cell levels in the peripheral blood | 6 months after transplant |
| Immune reconstitution by analyzing T, B, natural killer (NK), regulatory T cell levels in the peripheral blood | 12 months after transplant |
| Immune reconstitution by analyzing T, B, natural killer (NK), regulatory T cell levels in the peripheral blood | 24 months after transplant |
| Ferritine levels | At 3 months |
| Ferritine levels | At 6 months |
| Ferritine levels | At 12 months |
| Ferritine levels | At 24 months |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D052801 | Male Urogenital Diseases |
| D030342 | Genetic Diseases, Inborn |
| D009358 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities |
| D011677 | Punctures |
| D013514 | Surgical Procedures, Operative |
| D008919 | Investigative Techniques |